Overview

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out the effectiveness of the drug durvalumab (MEDI4736) with or without stereotactic body radiation therapy (SBRT) as treatment for stage I (tumors > 2cm), II, and IIIA non-small cell lung cancer (NSCLC) prior to surgery and one year following surgery.

Phase:

Phase 2

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Durvalumab